Quillichew ER vs. Aptensio XR

• Are Quillichew ER and Aptensio XR the Same Thing?
• What Are Possible Side Effects of Quillichew ER?
• What Are Possible Side Effects of Aptensio XR?
• What Is Quillichew ER?
• What Is Aptensio XR?
• What Drugs Interact with Quillichew ER?
• What Drugs Interact with Aptensio XR?
• How Should Quillichew ER Be Taken?
• How Should Aptensio XR Be Taken?

QuilliChew ER (methylphenidate hydrochloride) extended-release chewable tablets and Aptensio XR (methylphenidate hydrochloride extended-release) are central nervous system (CNS) stimulants used to treat attention deficit hyperactivity disorder (ADHD).

Side effects of QuilliChew ER and Aptensio XR that are similar include dizziness, rapid heart rate, decreased appetite, headache, nausea, vomiting, abdominal pain, sleep problems (insomnia), and fever.

Side effects of QuilliChew ER that are different from Aptensio XR include weight loss, anxiety, irritability, mood swings, aggression, indigestion, dry mouth, nervousness, restlessness, agitation, spinning sensation (vertigo), tremor, blurred vision, palpitations, increased sweating, and increased blood pressure.

Both QuilliChew ER and Aptensio XR may interact with monoamine oxidase inhibitors (MAOIs).

Withdrawal symptoms may occur if you suddenly stop taking QuilliChew ER or Aptensio XR.

Common side effects of Quillichew ER include:

• weight loss,
• anxiety,
• dizziness,
• irritability,
• mood swings,
• rapid heart rate,
• decreased appetite,
• aggression,
• headache,
• nausea,
• abdominal pain,
• indigestion,
• dry mouth,
• vomiting,
• insomnia,
• nervousness,
• restlessness,
• agitation,
• spinning sensation (vertigo),
• tremor,
• blurred vision,
• palpitations,
• increased sweating,
• fever, and
• increased blood pressure.

Common side effects of Aptensio XR include:

• abdominal pain,
• fever,
• decreased appetite,
• nausea,
• vomiting,
• headache,
• insomnia,
• dizziness, and
• rapid heart rate

QuilliChew ER (methylphenidate hydrochloride) extended-release chewable tablets is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Aptensio XR (methylphenidate hydrochloride extended-release) is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

QuilliChew ER may interact with monoamine oxidase inhibitors (MAOIs). Tell your doctor all medications and supplements you or your child uses. During pregnancy, QuilliChew ER should be used only if prescribed. It is unknown if it would affect a fetus. QuilliChew ER passes into breast milk. It is unknown if it would affect a nursing infant. Consult your doctor before breastfeeding. Withdrawal symptoms may occur if you suddenly stop taking QuilliChew ER.

Aptensio XR may interact with monoamine oxidase inhibitors (MAOIs). Tell your doctor all medications and supplements you use. During pregnancy, Aptensio XR should be used only if prescribed. Premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers. Aptensio XR passes into breast milk and may have undesirable effects on a nursing infant. Consult your doctor before breastfeeding. Withdrawal symptoms may occur if you suddenly stop taking Aptensio XR.

For patients 6 years and above, the recommended starting dose of QuilliChew ER is 20 mg given orally once daily in the morning.

The recommended starting dose of Aptensio XR for patients 6 years and above is 10 mg once daily with or without food in the morning. Dosage may be increased weekly in increments of 10 mg per day. Daily dosage above 60 mg is not recommended.